Research & innovation
Follow the evidence.
Pursue what’s next.
Our scientific interests span tumor biology, emerging technologies, and the path from a promising idea to a meaningful clinical advance.
A focused research agenda
Ambition, held to a
scientific standard.
Neuroendocrine cancers differ in origin, differentiation, grade, and biology. Advancing treatment means understanding those differences—and designing research that can reveal who benefits, why, and for how long.
We aim to support work with a credible mechanism, a clear unmet need, rigorous methods, and a realistic path toward clinical impact.
01Pancreatic & metastatic NETsEstablished care · unmet needs
Well-differentiated neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas are biologically different diseases. Our prospective focus is pancreatic and metastatic NETs: disease heterogeneity, treatment resistance, durable disease control, and quality of life.
Which disease features can help match a patient to the right therapeutic strategy?Explore the evidence (opens in a new tab)
02Histotripsy & tumor ablationClinical application · investigational immune effects
Histotripsy uses focused ultrasound to mechanically destroy liver tumor tissue. Its use for liver tumor destruction has FDA authorization. Whether it can generate clinically meaningful systemic antitumor immunity, especially in NETs, remains investigational; local tumor destruction does not establish a cure or a survival benefit.
Can rigorously designed studies connect local ablation with measurable systemic immune effects?Explore the evidence (opens in a new tab)
03Immunotherapy & the microenvironmentEarly clinical & preclinical research
Many well-differentiated NETs respond infrequently to single-agent checkpoint inhibition. Tumor genomics, immune-cell composition, and disease differentiation matter. Combination strategies, immunogenic cell death, and immune activation require careful preclinical and human evaluation.
What would it take to make an immunologically quiet tumor more responsive?Explore the evidence (opens in a new tab)
04Targeted radionuclide therapyEstablished PRRT · emerging approaches
Peptide receptor radionuclide therapy (PRRT) is an established option for selected somatostatin receptor-positive gastroenteropancreatic NETs. Research questions include treatment sequencing, dosimetry, resistance, and novel radiopharmaceuticals. Emerging alpha-emitting agents and combinations remain investigational.
How can patient selection and treatment design improve the therapeutic window?Explore the evidence (opens in a new tab)
05Genomics & precision therapeuticsClinical tools · evolving research
Molecular profiling, inherited predisposition, receptor expression, and circulating biomarkers can inform different aspects of care or research. A molecular finding does not guarantee an effective targeted treatment. Prospective validation and clinically meaningful endpoints are essential.
Which biomarkers can predict treatment benefit rather than simply describe disease?Explore the evidence (opens in a new tab)
06Translation & rational combinationsProspective research priority
We are interested in credible hypotheses with a clear path from mechanism to human investigation. This means reproducible methods, appropriate controls, safety monitoring, patient-centered endpoints, and transparent reporting—including negative findings. No institute-funded studies or trials are announced at this stage.
What evidence is needed to move a promising idea into a responsible clinical study?Explore the evidence (opens in a new tab)
Understanding the landscape
Build on progress.
Address the gaps.
Established options for selected patients may include surgery, somatostatin analogues, targeted medicines, chemotherapy, liver-directed treatment, and PRRT. Treatment depends on disease biology, extent, symptoms, previous therapies, and a specialist’s assessment. [1]
In March 2025, the FDA approved cabozantinib for previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-pancreatic NETs in adults and patients aged 12 years and older. [2]
Important needs remain: durable control of metastatic disease, better predictors of response, treatment resistance, and approaches that preserve quality of life. Our role is to help advance responsible research into those questions.
Explore research perspectivesHow we communicate science
Evidence should be visible.
Established clinical evidence
Relevant approved uses and robust human trials. Applicability still depends on the population and indication.
Emerging clinical evidence
Early, small, or nonrandomized human studies. Findings need confirmation and careful interpretation.
Preclinical research
Studies in cells, tissues, or animals. These findings do not establish benefit in patients.
Research hypothesis
A plausible question or proposed mechanism that has not yet been demonstrated.
A promising question deserves
a rigorous conversation.
We welcome nonconfidential research concepts and collaboration inquiries.
Explore scientific collaborationLooking for clinical trials?
Explore registered studies and discuss eligibility with your treating team. Listings are independent of the institute and do not establish effectiveness.
Explore ClinicalTrials.gov (opens in a new tab)